Kallikrein-kinin in stroke, cardiovascular and renal disease

Experimental Physiology

Volumn 90, Issue 3, 2005, Pages 291-298

  Chao, Julie ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIC AMP; CYCLIC GMP; CYTOKINE; ICATIBANT; KALLIKREIN; NITRIC OXIDE; PLASMID DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

BLOOD PRESSURE REGULATION; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; GENE DELIVERY SYSTEM; GENE TRANSFER; GENETIC MANIPULATION; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; NEUROLOGIC DISEASE; NONHUMAN; RENAL PROTECTION; RESTENOSIS; REVIEW; STROKE;

EID: 18844368834     PISSN: 09580670     EISSN: None     Source Type: Journal    
DOI: 10.1113/expphysiol.2004.028464     Document Type: Review

References (72)

1. Agata J, Chao L & Chao J (2002). Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40, 653-659.
2. Alfie ME, Yang X, Hess F & Carretero OA (1996). Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224, 625-630.
3. Bell RM & Yellon DM (2003). Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35, 185-193.
4. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H & Williams RR (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 3-8.
5. Bhoola KD, Figueroa CD & Worthy K (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44, 1-80.
6. Bledsoe G, Chao L & Chao J (2003). Kallikrein gene delivery attenuates cardiac remodeling and. promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 285, H1479-H1488.
7. Bouhnik J, Richoux JP, Huang H, Savoie F, Baussant T, AJhenc-Gelas F & Corvol P (1992). Hypertension in Dahl salt-sensitive rats: biochemical and immunohistochemical studies. Clin Sci 83, 13-22.
8. Chao J, Jin L, Chen LM, Chen VC & Chao L (1996). Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther 7, 901-911.
9. Chao J, Stallone JN, Liang Y-M, Chen L-M & Chao L (1997). Kallistatin is a potent new vasodilator. J Clin Invest 100, 11-17.
10. Chao J, Tillman DM, Wang MY, Margolius HS & Chao L (1986). Identification of a new tissue kallikrein-binding protein. Biochem J 239, 325-331.
11. Chao J, Zhang J, Lin KF & Chao L (1998a). Adenovirus-mediated kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9, 21-31.
12. Chao J, Zhang JJ, Lin KF & Chao L (1998b). Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54, 1250-1260.
13. Couture R, Harrisson M, Vianna RM & Cloutier F (2001). Kinin receptors in pain and inflammation. Eur J Pharmacol 429, 161-176.
14. Dobrzynski E, Yoshida H, Chao J & Chao L (1999). Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology 44, 57-65.
15. Elliot R & Nuzum F (1934). Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462-474.
16. Emanueli C, Bonaria Salis M, Stacca T, Gaspa L, Chao J, Chao L, Pinna A & Madeddu P (2001b). Rescue of Impaired Angiogenesis in spontaneously hypertensive rats by intramuscular human. Hypertension 38, 136-141.
17. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, Salis MB, Straino S, Capogrossi MC, Olivetti G & Madeddu P (1999). Dilated and failing cardiomyopathy in bradykinin B (2) receptor knockout mice. Circulation 100, 2359-2365.
18. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Bonaria Salis M, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC & Madeddu P (2001a). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125-132.
19. Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munao A, Straino S, Minasi A, Capogrossi MC & Madeddu P (2000). Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol 20, 1459-1466.
20. Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L & Madeddu P (2002). Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 106, 993-999.
21. Farhy RD, Carretero OA, Ho KL & Scicli AG (1993). Role of kinins and nitric oxide in the effects of angiotensiri converting enzyme inhibitors on neointima formation. Circles 72, 1202-1210.
22. Favaro S, Baggio B, Antonello A, Zen A, Cannella G, Todesco S & Borsatti A (1975). Renal kallikrein content of spontaneously hypertensive rats. Clin Sci Mol Med 49, 69-71.
23. Fisher M (2002). Developing therapy for acute ischemic stroke. Therapie 57, 564-568.
24. Gavras I & Gavras H (1988). Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int 34, S60-S62.
25. Gilboa N, Rudofsky UH, Phillips MI & Magro AM (1989). Modulation of urinary kallikrein and plasma reniii activities does not affect established hypertension in the Fawn-Hooded rat. Nephron 51, 61-66.
26. Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, Ikeda T, Kizuki K & Omata M (1999). Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 81, 183-193.
27. Jin L, Zhang JJ, Chao L & Chao J (1997). Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8, 1753-1761.
28. Linz W & Scholkens BA (1992). Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20, S83-S90.
29. Madeddu P, Varoni MV, Dementis MP, Chao J, Simson JA, Glorioso N & Anania V (1997). Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29, 471-477.
30. Majima M, Mizogami S, Kuribayashi Y, Katori M & Oh-ishi S (1994). Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24, 111-119.
31. Marceau F (1995). Kinin B1 receptors: a review. Immunopharmacology 30, 1-26.
32. Margolius HS (1989). Tissue kallikreins and kinins regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol 29, 343-364.
33. Martorana PA, Kettenbach B, Breipohl G, Linz W, & Scholkens BA (1990). Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182, 395-396.
34. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A 98, 2634-2639.
35. Miao RQ, Agata J, Chao L & Chao J (2002). Kallistatin is a new endogenous inhibitor of angiogenesis and tumor growth. Blood 100, 3245-3252.
36. Miao RQ, Murakami H, Song Q, Chao L & Chao J (2000). Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res 86, 418-424.
37. Murakami H, Miao RQ, Chao L & Chao J (1999a). Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology 44, 137-143.
38. Murakami H, Yayama K, Chao L & Chao J (1998). Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 53, 1305-1313.
39. Murakami H, Yayama K, Miao RQ, Wang C, Chao L & Chao J (1999b). Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34, 164-170.
40. Naicker S, Naidoo S, Ramsaroop R, Moodley D & Bhoola K (1999). Tissue kallikrein and kinins in renal disease. Immunopharmacology 44, 183-192.
41. Overlack A, Stumpe KO, Kolloch R, Ressel C & Krueck F (1981). Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 3, 118-121.
42. Overlack A, Stumpe KO, Ressel C, Kolloch R, Zywzok W & Kruck F (1980). Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin Wochenschr 58, 37-42.
43. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA, Walther T, Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR & Bader M (2000). Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97, 8140-8145.
44. Powers CA, Baer PG & Nasjletti A (1984). Reduced glandular kallikrein-like activity in the anterior pituitary of the New Zealand genetically hypertensive rat. Biochem Biophys Res Commun 119, 689-693.
45. Pravenec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L & Kurtz TW (1991). Cosegregation of blood pressure with a kallikrein gene family. Hypertension 17, 242-246.
46. Price RG (1982). Urinary enzymes, nephrotoxicity and renal disease. Toxicology 23, 99-134.
47. Regoli D, Rhaleb NE, Drapeau G & Dion S (1990). Kinin receptor subtypes. J Cardiovasc Pharmacol 15, S30-S38.
48. Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschope C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB & Bader M (2000). Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14, 1858-1860.
49. Song Q, Chao J & Chao L (1996). High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens 18, 975-993.
50. Song Q, Chao J & Chao L (1997). DNA polymorphisms in the 5(flanking region of human tissue kallikrein gene, (RN96-013). Hum Genet 99, 727-734.
51. Song Q, Hunt SC, Zheng D, Williams GH, Chao J & Chao L (2005). A promoter polymorphism of human tissue kallikrein gene is associated with the response of blood pressure to dietary salt restriction. Physiol Genomics (in press).
52. Souza DG, Lomez ESL, Pinho V, Pesquero JB, Bader M, Pesquero JG & Teixeira MM (2004). Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 172, 2542-2548.
53. Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, Ikeda T, Goto A, Toyo-oka T, Kizuki K & Omata M (1994). Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24, 770-778.
54. Wang C, Chao L & Chao J (1995). Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95, 1710-1706.
55. Wang C, Chao C, Madeddu P, Chao L & Chao J (1998). Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun 244, 449-454.
56. Wang D, Chao J & Chao L (1997). Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29, 488-493.
57. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J & Chao L (1994). Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243.
58. Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X & Wang DW (2004). Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11, 1342-1350.
59. Wolf WC, Yoshida H, Agata J, Chao L & Chao J (2000). Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58, 730-739.
60. Woodley-Miller C, Chao I & Chao L (1989). Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens 7, 865-871.
61. Xia CF, Yin H, Borlongan CV, Chao L & Chao J (2004). Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43, 452-459.
62. Xiong W, Chao I & Chao L (1995). Muscle delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25, 715-719.
63. Yayama K, Wang C, Chao L & Chao J (1998). Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31, 1104-1110.
64. Yin H, Chao L & Chao J (2005). Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-GSK-3 and Akt-Bad-14-3-3 signaling pathways. J Biol Chem 280, 8022-8030.
65. Yoshida H, Zhang JJ, Chao L & Chao J (2000). Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35, 25-31.
66. Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS & Bowden DW (2002). Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 61, 1030-1039.
67. Zhang JJ, Bledsoe G, Kato K, Chao L & Chao I (2004). Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66, 722-732.
68. Zhang JJ, Chao L & Chao I (1999). Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke 30, 1925-1931.
69. Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW & Zeldin DC (2003). Gene therapy with tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 42, 1026-1033.
70. Zhou GX, Chao L & Chao J (1992). Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267, 25873-25880.
71. Zinner SH, Margolius HS, Rosner B & Kass EH (1978). Stability of blood pressure rank and urinary kallikrein concentration in childhood. Circulation 58, 908-915.
72. Zinner SH, Margolius HS, Rosner B, Keiser HR & Kass EH (1976). Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 104, 124-132.